Thymidylate synthase pharmacogenetics

SummaryThymidylate synthase (TYMS) is an important target for chemotherapy drugs, such as 5-fluorouracil (5FU) and methotrexate. Over-expression of TYMS is linked to resistance to TYMS-targeted chemotherapy drugs. Currently there is no protocol for selecting cancer patients at risk for drug resistance prior to chemotherapy treatment. Three polymorphisms in the 5′ and 3′ untranslated regions (5′UTR and 3′UTR) of the thymidylate synthase gene have been shown to influence TYMS expression. Preliminary data has suggested a poorer response rate to 5FU or methotrexate is seen in patients with 3 copies of a 28 bp tandem repeat in the 5′UTR enhancer region (TSER polymorphism) and this relationship may be further clarified by the presence of a single nucleotide polymorphism (SNP) with the second repeat of the 3 repeat (TSER*3) allele. A 6 bp deletion in the 3′UTR of the TYMS gene has also been shown to affect TYMS RNA expression and has a significant association with poor outcome in 5FU treated patients. Evidence linking all 3 TYMS polymorphisms with TYMS expression and patient response to TYMS-targeted chemotherapy treatment will be highlighted.

[1]  P. Johnston,et al.  Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. , 1992, Cancer research.

[2]  O. Gotoh,et al.  Structural and functional analysis of the human thymidylate synthase gene. , 1990, The Journal of biological chemistry.

[3]  J. García-Foncillas,et al.  Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  L. Jorde,et al.  Length Polymorphism of Thymidylate Synthase Regulatory Region in Chinese Populations and Evolution of the Novel Alleles , 2002, Biochemical Genetics.

[5]  S. Groshen,et al.  Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy , 2001, The Pharmacogenomics Journal.

[6]  M. Krajinovic,et al.  The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia. , 2003, Pharmacogenetics.

[7]  D. Sargent,et al.  pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5fu)/cpt-11, 5fu/oxaliplatin (oxal), or Cpt-11/oxal therapy for advanced colorectal cancer (crc): Results from an intergroup trial : 1013 , 2003 .

[8]  B. Iacopetta,et al.  A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil , 2001, British Journal of Cancer.

[9]  H. McLeod,et al.  Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. , 2001, International journal of oncology.

[10]  K. Kawakami,et al.  Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. , 1999, Anticancer research.

[11]  C. Ulrich,et al.  Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[12]  S. Hidaka,et al.  Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  E. Chu,et al.  Thymidylate Synthase Pharmacogenetics in Colorectal Cancer. , 2001, Clinical colorectal cancer.

[14]  S. Groshen,et al.  Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Howard L McLeod,et al.  Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.

[16]  H. McLeod,et al.  Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. , 1999, Genomics.

[17]  J. Watters,et al.  Recent advances in the pharmacogenetics of cancer chemotherapy. , 2002, Current opinion in molecular therapeutics (Print).

[18]  R. Gelber,et al.  Prognostic importance of thymidylate synthase expression in early breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  H. Lenz,et al.  Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. , 1997, Cancer letters.

[20]  F. Maley,et al.  Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  H E Rockette,et al.  The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Groshen,et al.  Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Altman,et al.  Role in translation of a triple tandemly repeated sequence in the 5'-untranslated region of human thymidylate synthase mRNA. , 1987, Nucleic acids research.

[24]  H. McLeod,et al.  Novel thymidylate synthase enhancer region alleles in African populations , 2000, Human mutation.

[25]  P. Johnston,et al.  Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. , 1995, Cancer research.

[26]  O. Gotoh,et al.  Human thymidylate synthase gene: isolation of phage clones which cover a functionally active gene and structural analysis of the region upstream from the translation initiation codon. , 1989, Journal of biochemistry.

[27]  M. Krajinovic,et al.  Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia , 2002, The Lancet.

[28]  N. Horie,et al.  Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. , 1995, Cell structure and function.

[29]  G. Watanabe,et al.  Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  S. Marsh,et al.  Cancer pharmacogenetics , 2004, British Journal of Cancer.

[31]  T. Seno,et al.  Regulatory sequences clustered at the 5′ end of the first intron of the human thymidylate synthase gene function in cooperation with the promoter region , 1992, Somatic cell and molecular genetics.

[32]  G. Watanabe,et al.  Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. , 2003, Cancer research.

[33]  Howard L McLeod,et al.  Cancer pharmacogenomics: current and future applications. , 2003, Biochimica et biophysica acta.